Patents Assigned to BIO-THERA SOLUTIONS, LTD., CO.
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
    Publication number: 20170258935
    Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Applicant: Bio-Thera Solutions, Ltd., Co.
    Inventors: Weijia Tang, Shengfeng Li, Jin-Chen Yu, Xiaobin Deng
  • Compounds and methods for the treatment of ERB B2/NEU positive diseases
    Patent number: 9737616
    Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: August 22, 2017
    Assignee: Bio-Thera Solutions, Ltd., Co.
    Inventors: Weijia Tang, Shengfeng Li, Jin-Chen Yu, Xiaobin Deng
  • Maytansinoid derivatives
    Patent number: 9345786
    Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 24, 2016
    Assignee: Bio-Thera Solutions, Ltd., Co.
    Inventors: Shengfeng Li, Xiaobin Deng, Songnuan Tan, Weijia Tang, Chao Qin
  • Compounds and methods for the treatment of EGFR positive diseases
    Patent number: 9314536
    Abstract: Disclosed herein are anti-EGFR antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat EGFR positive cells in cancers are provided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 19, 2016
    Assignee: Bio-Thera Solutions, Ltd., Co.
    Inventors: Chao Qin, Shengfeng Li
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
    Publication number: 20150320881
    Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
    Type: Application
    Filed: July 17, 2015
    Publication date: November 12, 2015
    Applicant: BIO-THERA SOLUTIONS, LTD., CO.
    Inventors: Weijia Tang, Shengfeng Li, Jin-Chen Yu, Xiaobin Deng
  • Preparation of maytansinoid esters
    Patent number: 8889855
    Abstract: Provided are efficient methods for direct coupling of a maytansinoid with a carboxylic acid to prepare a maytansinoid C-3 ester in high yield using a rare earth metal-based or trifluoromethanesulfonate-based Lewis acid catalyst and a base together with a coupling reagent. Also provided are compositions used in such methods.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 18, 2014
    Assignee: Bio-Thera Solutions Ltd., Co.
    Inventor: Xiaobin Deng
  • Maytansinoid derivatives
    Patent number: 8877706
    Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 4, 2014
    Assignee: Bio-Thera Solutions Ltd., Co.
    Inventors: Shenfeng Li, Xiaobin Deng, Songnuan Tan, Weijia Tang, Chao Qin
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF CD20 POSITIVE DISEASES
    Publication number: 20140178411
    Abstract: Disclosed herein are anti-CD20 antibody conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat CD20 positive cells in cancers are provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 26, 2014
    Applicant: BIO-THERA SOLUTIONS, LTD., CO.
    Inventors: Chao Qin, Shengfeng Li
  • PREPARATION OF MAYTANSINOID ESTERS
    Publication number: 20140179917
    Abstract: Provided are efficient methods for direct coupling of a maytansinoid with a carboxylic acid to prepare a maytansinoid C-3 ester in high yield using a rare earth metal-based or trifluoromethanesulfonate-based Lewis acid catalyst and a base together with a coupling reagent. Also provided are compositions used in such methods.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 26, 2014
    Applicant: BIO-THERA SOLUTIONS, LTD., CO.
    Inventor: Xiaobin DENG
  • MAYTANSINOID DERIVATIVES
    Publication number: 20140178414
    Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 26, 2014
    Applicant: BIO-THERA SOLUTIONS, LTD., CO.
    Inventor: BIO-THERA SOLUTIONS, LTD., CO.
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
    Publication number: 20140178413
    Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 26, 2014
    Applicant: BIO-THERA SOLUTIONS, LTD., CO.
    Inventor: Bio-Thera Solutions, Ltd. Co.